Request A Call Back
Product Description
Nindanix is the first global generic of Nintedanib which is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy/immunotherapy and when no driver mutation is found to target.